

ORIGINAL RESEARCH

The histaminergic system is involved in psychological stress-induced hyperthermia in rats

Battuvshin Lkhagvasuren^{1,2} & Takakazu Oka¹¹ Department of Psychosomatic Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan² The Neuroscience Cluster, Science and Technology Center, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia**Keywords**

Circadian rhythm, histamine, locomotor activity, stress, temperature, thermoregulation.

Correspondence

Takakazu Oka, Department of Psychosomatic Medicine, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, 8128582 Fukuoka, Japan.

Tel: 81-92-642-5317

Fax: 81-92-642-5336

E-mail: oka-t@cephal.med.kyushu-u.ac.jp

Funding Information

This study was supported by Grants-in-Aid for Scientific Research (23390189 to T.O.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and Grants-in-Aid for Scientific Research (In-01/2015 to B.L.) from the Ministry of Education, Culture, and Science of Mongolia.

Received: 20 October 2016; Revised: 19 February 2017; Accepted: 20 February 2017

doi: 10.14814/phy2.13204

Physiol Rep, 5 (8), 2017, e13204,
doi: 10.14814/phy2.13204

Introduction

Many kinds of psychological stress increase core body temperature (T_c) in mammals such as rats (Briese and de Quijada 1970; Vinkers et al. 2009), mice (Zethof et al. 1995; Oka et al. 2003), rabbits (Yokoi 1966; Snow and Horita 1982), and humans (McNeil et al. 1984; Timmerman et al. 1992; Oka and Oka 2007; Hiramoto et al. 2009; Kaneda et al. 2009). For example, in rats, cage

Abstract

The histaminergic system modulates numerous physiological functions such as wakefulness, circadian rhythm, feeding, and thermoregulation. However, it is not yet known if this system is also involved in psychological stress-induced hyperthermia (PSH) and, if so, which histamine (H) receptor subtype mediates the effect. Therefore, we investigated the effects of pretreatments with intraperitoneal injections of mepyramine (an H1 receptor inverse agonist), cimetidine (an H2 receptor antagonist), and ciproxifan (an H3 receptor inverse agonist) on cage-exchange stress-induced hyperthermia (a model of PSH) by monitoring core body temperature (T_c) during both light (10:00 AM–12:00 PM) and dark (10:00 PM–12:00 AM) phases in conscious, freely moving rats. We also investigated the effects of these drugs on stress-induced changes in locomotor activity (L_a) to rule out the possibility that effects on T_c are achieved secondary to altered L_a . Cage-exchange stress increased T_c within 20 min followed by a gradual decrease back to baseline T_c during both phases. In the light phase, mepyramine and cimetidine markedly attenuated PSH, whereas ciproxifan did not affect it. In contrast, in the dark phase, mepyramine dropped T_c by 1°C without affecting cage-exchange stress-induced hyperthermia, whereas cimetidine and ciproxifan did not affect both postinjection T_c and PSH. Cage-exchange stress induced an increase in L_a , especially in the light phase, but none of these drugs altered cage-exchange stress-induced L_a in either circadian rhythm phase. These results suggest that the histaminergic system is involved in the physiological mechanisms underlying PSH, particularly through H1 and H2 receptors, without influencing locomotor activity.

exchange stress, that is, exchanging home cages between two animals (Long et al. 1990a), or social defeat stress, that is, exposure to dominant conspecific animals (Lkhagvasuren et al. 2011), induces a robust increase in T_c up to 2°C within 30 min. This phenomenon is known as psychological stress-induced hyperthermia (PSH). PSH may have adaptive and beneficial values for animals to survive “fight-or-flight” situations because such rapid increases in T_c in a stressful situation helps to warm up muscular and

central nervous systems, leading to increased physical and neurocognitive performance (Wright et al. 2002; Bishop 2003; Kataoka et al. 2014).

Recently, neural mechanisms underlying PSH have been extensively studied. Anatomical studies have demonstrated that, at least in part, the dorsomedial hypothalamus (DMH) – rostral medullary raphe regions (which include the rostral raphe pallidus and the raphe magnus nuclei) – sympathetic nerve axis, is involved in the development of PSH by inducing nonshivering thermogenesis in brown adipose tissue (Cannon and Nedergaard 2004; Lkhagvasuren et al. 2011; Kataoka et al. 2014). Sympathetic nerve-mediated peripheral vasoconstriction may also contribute to PSH via inhibiting heat loss (Oka et al. 2001). Of note, previous studies have shown that the mechanism responsible for PSH is different from inflammation-induced fever, which requires proinflammatory mediators (Oka et al. 2003). Pharmacological studies indicated that PSH is not attenuated by systemic administration of cyclooxygenase inhibitors, but is reduced by anxiolytic drugs such as benzodiazepines or serotonin (5-HT) 1A receptor agonists, β 3-adrenoceptor antagonists, or α -adrenoceptor antagonists (Oishi et al. 1992; Nakamori et al. 1993; Groenink et al. 1995; Oka et al. 2001; Lkhagvasuren et al. 2014). So far, however, the role of the histaminergic system in PSH is not known. Furthermore, it has not yet been investigated whether peripheral administration of antihistaminergic drugs affects PSH.

We hypothesized that the histaminergic system is involved in PSH, and that peripheral antihistaminergic drugs would attenuate PSH based on the following findings. First, in our previous study (Lkhagvasuren et al. 2014), we observed that social defeat stress increases T_c and *Fos* protein expression, a marker of neuronal activation (Sagar et al. 1988), in the tuberomammillary nucleus (TMN), from where histaminergic projections originate, in rats. Furthermore, intraperitoneal (IP) injection of diazepam attenuated both PSH and *Fos* expression in the TMN (Lkhagvasuren et al. 2014). Second, histaminergic neurons in the TMN are involved in arousal (McGinty et al. 2001; Haas et al. 2008; Panula and Nuutinen 2013) and it has been demonstrated that goal-directed behavioral arousal, such as food anticipation, is accompanied by activation of histaminergic neurons in the TMN and increased T_c (Valdes et al. 2010).

The histamine (H) receptor has four subtypes, that is, H1, H2, H3, and H4 receptors (Hill et al. 1997). Among them, H1, H2, and H3 receptors are known to be distributed within the brain (Haas et al. 2008; Panula and Nuutinen 2013). However, distribution of H4 receptors in the central nervous system is still controversial (Schneider and Seifert 2016). Therefore, we were determined to elucidate the role of H1, H2, and H3 receptors in PSH by

investigating the effects of IP injection of mepyramine (an H1 receptor inverse agonist), cimetidine (an H2 receptor antagonist), and ciproxifan (an H3 receptor inverse agonist) on cage-exchange stress-induced hyperthermia in conscious, freely moving rats. In this experiment, we chose cage-exchange stress because this procedure has been widely accepted as a model of PSH (Long et al. 1990a; Oka et al. 2003), and the magnitude of cage-exchange stress-induced PSH is stable and reproducible (Oka et al. 2003). We also assessed the role of H1, H2, and H3 receptors on stress-induced hyperkinesia because cage-exchange stress increases locomotor activity (L_a), especially during the light period (Long et al. 1990b). Moreover, some, but not all studies have shown that the histaminergic system modulates locomotor activity (O'Neill and Gertner 1987; Yanai et al. 1998; Toyota et al. 2002). Previous studies have suggested that PSH represents an independent stress response distinct from hyperkinesia (Long et al. 1990b; Houtepen et al. 2011). However, it is not known whether antihistamine drugs can affect L_a at doses that affect PSH, and vice versa. Therefore, we also investigated the effects of antihistaminergic drugs on L_a as well as PSH. Since the histaminergic system is involved in the establishment and maintenance of circadian rhythms (Mochizuki et al. 1992), we conducted our experiments during both light and dark circadian phases.

Materials and Methods

Animal procedures, diet, and housing

Male Wistar rats weighing 170–190 g (SLC, Kurume, Japan) were used for the following experiments. The rats were individually housed in plastic cages (a cage: 40 cm long \times 25 cm wide \times 20 cm high) in a room air-conditioned at $26 \pm 1^\circ\text{C}$ with a standard 12-h light–dark cycle (lights on 7:00 AM – 7:00 PM) and allowed ad libitum access to food and water. All procedures conformed to the guidelines of animal care by Kyushu University and were approved by the Ethics Committees of Kyushu University.

Monitoring of T_c and L_a

We measured T_c and L_a of the rats using a telemetry system while the animals were freely moving (Data Sciences International, St. Paul, MN). A battery-operated telemetry transmitter (TA10TA-F40) was implanted into the peritoneal cavity of each rat via a midline incision under anesthesia with a mixture (0.1 mL/10 g weight, IP) of medetomidine (0.15 mg/kg), midazolam (2 mg/kg), and butorphanol (2.5 mg/kg). After closure of the cavity with

a suture, the rats were housed individually for a week to recover from the surgery under regular health checks. T_c and L_a signals were received by an antenna below a rat cage and relayed to a signal processor connected to a server computer. At least 1 day before the experiment, the telemetric transmitters were activated using a magnet to start sampling T_c ($^{\circ}\text{C}$) and L_a (counts/min) every 5 min. L_a counts reflect all movements both in horizontal and vertical directions. Only rats that showed stable circadian rhythm changes in T_c and L_a were used for the following experiments. On the experimental day, both T_c and L_a were monitored for 24 h.

Drug injections

On the experimental day, rats received an IP injection of mepyramine (an H1 receptor inverse agonist, 30 mg/kg, 0.15–0.2 mL; Wako, Osaka, Japan [synonym: pyrillamine]), cimetidine (an H2 receptor antagonist, 100 mg/kg, 0.35–0.4 mL; Wako, Osaka, Japan), ciproxifan (an H3 receptor inverse agonist, 10 mg/kg, 0.15–0.2 mL; Sigma, San Francisco), or one of their respective vehicles. To investigate the role of H1 and H3 receptors in the development of PSH, we administered an H1 receptor inverse antagonist and an H3 receptor inverse agonist, respectively. Inverse agonists are molecules that bind to the same receptor as agonists but induce the pharmacological responses opposite to the agonists. Therefore, H1 and H3 inverse agonists have opposite effects to H1 and H3 receptor agonists, respectively. Mepyramine, permeable to the blood-brain barrier (BBB) via carrier-mediated transport (Yamazaki et al. 1994), and ciproxifan, also permeable to the BBB (Ligneau et al. 1998), were dissolved in physiological saline, whereas cimetidine, also permeable to the BBB (Whittico et al. 1990), was dissolved first in physiological saline with 0.1N hydrochloric acid, then neutralized with sodium hydroxide (Owen et al. 1980). Since previous studies that investigated the effects of histaminergic drugs on T_c or L_a are limited and the results are controversial (Clark and Clark 1980; Clark and Lipton, 1985), we were determined to investigate the effect of a maximal dose of each drug on PSH. Therefore, to begin, we researched the effective dose of each drug (administered intraperitoneally) to investigate their physiological effects in established literature. Then, we investigated the effects of histaminergic drugs at that dose (and higher doses) in freely moving rats in both circadian periods. IP injection of mepyramine at doses greater than 30 mg/kg caused sudden death by abrupt seizures in the dark phase, which was in line with previous studies that demonstrated the proconvulsive effect of H1 antagonists/inverse agonists (Kamei et al. 2000; Haruyama et al.

2008). Therefore, we selected 30 mg/kg for mepyramine (Clark and Clark 1980; Clark and Lipton 1985a; Masuoka et al. 2008). Our pilot study found that the effects of IP injection of cimetidine and ciproxifan at doses widely used in the literature, that is, 30 mg/kg for cimetidine (Clark and Clark 1980) and 3 mg/kg for ciproxifan (Ligneau et al. 1998; Morisset et al. 2000; Fox et al. 2005), and at the maximal doses used in the literature, that is, 100 mg/kg for cimetidine (Hough et al. 1985) and 10 mg/kg for ciproxifan (Esbenshade et al. 2004), on T_c and L_a were similar. Therefore, in this study, we show the results obtained by the higher doses. To minimize the stress of the IP injection procedures, solutions were injected into the lower abdomen, which was exposed to the experimenter by gently bending the lower back backward with the base of the tail lifted up. This procedure was performed within the home cages of the rats while their forelegs were still touching the floor, to avoid moving the head of the rats upside down. Thus, mostly, the PSH following from the IP injection procedure was less than 0.5°C , which enabled us to observe the development of subsequent cage-exchange stress-induced hyperthermia.

Cage-exchange stress

Thirty minutes after the injection, rats were either exposed to cage-exchange stress (Stress exposure) or left undisturbed in their home cages (Control exposure). The cage-exchange stress procedure is described in detail elsewhere (Oka et al. 2003). In brief, this was evoked by exchanging the home cages of two rats for 60 min. Thereafter, the rats were returned to their home cages. The experiments were performed between 10:00 AM and 12:00 PM in the light phase and between 10:00 PM and 12:00 AM in the dark phase, when the circadian rhythm changes in T_c are minimal. The rats were randomly separated into four groups ($n = 4$ –8 per group) and each group was first IP injected either with a vehicle or drug, then treated either with the control or the stress exposure to produce the following groups: (1) a vehicle injection followed by control exposure (Vehicle/Control group); (2) a vehicle injection followed by stress exposure (Vehicle/Stress group); (3) a drug injection followed by stress exposure (Drug/Stress group); (4) a drug injection followed by control exposure (Drug/Control group).

The average T_c for a 30-min period prior to the injection was considered the baseline T_c . The average T_c for a 30-min period after the injection was considered the postinjection T_c . In the same way, the average L_a for a 30-min period prior to the injection was determined as the baseline L_a . The average L_a for a 30-min period after the injection was determined the postinjection L_a .

Statistical analysis

All data are presented as means \pm standard error of the means. The effects of stress/control exposure on T_c across time were evaluated using two-way repeated measures ANOVA (groups, time, groups \times time) followed by Bonferroni *post hoc* test or unpaired *t*-test. Differences in baseline T_c and postinjection T_c were analyzed using an unpaired *t*-test or one-way ANOVA with Bonferroni *post hoc* test, if appropriate. The effects of drugs on postinjection T_c within a group were analyzed using a paired *t*-test. The same analyses were completed for L_a . All tests were two-tailed and results with *P* values of < 0.05 were considered significant (SPSS Statistics, Version 21).

Results

The effects of cage-exchange stress on T_c and L_a

Light phase

Baseline T_c was not different between Saline/Stress group ($n = 5$) and Saline/Control group ($n = 4$). Saline injection did not change the postinjection T_c in either group and there was no difference in postinjection T_c between

the two groups. However, cage-exchange stress induced a rapid increase in T_c in the stressed rats, peaking at 20 min. Two-way repeated measures ANOVA of the 60 min during the stress/control exposure demonstrated that there was a significant difference in T_c across time between the two groups (groups: $F_1 = 24.68$, $P < 0.002$; time: $F_{2,2} = 5.71$, $P = 0.012$; groups \times time: $F_{2,2} = 8.07$, $P = 0.003$). Additional *post hoc* analysis using unpaired *t*-testing of the 90 min including 60 min during the stress/control exposure and subsequent 30 min afterward revealed significant differences from 10 min to 90 min between the two groups (Fig. 1A). Baseline L_a was not different between the two groups, either. Saline injection induced an increase in the postinjection L_a in both groups (control: $t_3 = -8.16$, $P = 0.004$; stress: $t_4 = -3.04$, $P = 0.016$; paired *t*-test), although there was no difference between the two groups. Cage exchange stress induced a rapid increase in L_a in the stressed rats, peaking at 10 min. Two-way repeated measures ANOVA revealed that the Saline/Stress group had a significantly greater L_a (groups: $F_1 = 8.61$, $P = 0.014$, time: $F_{4,27} = 3.01$, $P = 0.025$, groups \times time: $F_{4,27} = 1.97$, $P = 0.11$) during the stress/control exposure across time when compared with the Saline/Control group. The *post hoc* test indicated significant differences at the indicated time points between the two groups (Fig. 1C).




Figure 1. Effects of cage-exchange stress on T_c (A and B) and L_a (C and D) in light and dark phases in rats. Rats ($n = 4-7$ per group) were administered an IP injection of physiological saline at time -30 min (arrows), either exposed to cage-exchange stress (Stress: filled circles) or left undisturbed (Control: empty circles) at time zero for 60 min (black bar), then returned to their home cages in the light (A and C) and dark (B and D) phases. Each point represents mean \pm S.E.M. The differences in both T_c and L_a between the two groups were compared using two-way repeated-measures ANOVA followed by unpaired *t*-test ($*P < 0.05$, $**P < 0.01$). *N* in the parentheses = number of animals.

Dark phase

Baseline T_c was not different between Saline/Stress group ($n = 4$) and Saline/Control group ($n = 7$). Saline injection did not change the postinjection T_c in either group and there was no difference in postinjection T_c between the two groups. Cage exchange stress induced a rapid increase in T_c in the stressed rats, peaking at 20 min. Two-way repeated measures ANOVA of the 60 min during the stress/control exposure revealed that the stressed rats had a significantly greater increase in T_c (groups: $F_1 = 14.84$, $P = 0.004$, time: $F_{2.85} = 4.41$, $P = 0.013$, groups \times time: $F_{2.85} = 9.68$, $P < 0.001$) when compared with the undisturbed rats. Additional *post hoc* analysis using unpaired *t*-testing of the 90 min including 60 min during the stress/control exposure and subsequent 30 min afterward indicated significantly higher values in T_c from 20 min to 85 min in the stressed rats versus the undisturbed controls (Fig. 1B). Baseline L_a was not different between the two groups. Saline injection did not change the postinjection L_a in either group and there was no difference in postinjection L_a between the two groups. Two-way repeated measures ANOVA of the 60 min during the stress/control exposure revealed that there was no difference in L_a between the two groups, although pairwise

comparison at each time-point with *t*-testing revealed significant differences at the indicated time points between the two groups (Fig. 1D).

The effects of antihistaminergic drugs on T_c and L_a during postinjection and cage-exchange stress periods

H1 receptor inverse agonist

Light phase

Baseline T_c did not differ among the four groups including Saline/Stress ($n = 5$), Saline/Control ($n = 4$), Mepyramine/Stress ($n = 5$), and Mepyramine/Control ($n = 4$) groups. IP injection of mepyramine did not affect the postinjection T_c in either the control group or the stress group. Two-way repeated measures ANOVA of the 60 min during the stress/control exposure followed by Bonferroni *post hoc* testing revealed that mepyramine significantly attenuated the cage-exchange stress-induced increase in T_c (groups: $F_3 = 15.4$, $P < 0.001$; time: $F_{2.41} = 8.17$, $P = 0.001$; groups \times time: $F_{7.24} = 4.12$, $P = 0.002$; Saline/Stress vs. Mepyramine/Stress: $P = 0.001$; Fig. 2A). Baseline L_a and postinjection L_a were not different among the four groups (Fig. 2C). Two-way repeated




Figure 2. Effects of mepyramine on the cage-exchange stress-induced changes in T_c (A and B) and L_a (C and D) in light and dark phases. Rats ($n = 4$ – 7 per group) were administered with either an IP injection of 30 mg/kg mepyramine (triangles) or physiological saline (circles) at time -30 min (arrows), either exposed to cage-exchange stress (Stress: filled circles) or left undisturbed (Control: empty circles) at time zero for 60 min (black bar), then returned to their home cages in the light (A and C) and dark (B and D) phases. Each point represents mean \pm S.E.M. The differences in both T_c and L_a among the groups were compared using two-way repeated measures ANOVA followed by Bonferroni *post hoc* test. N in the parentheses = number of animals.

measures ANOVA of the 60 min during the stress/control exposure followed by Bonferroni *post hoc* testing revealed that mepyramine did not affect the cage-exchange stress-induced increase in L_a (Mepyramine/Stress vs. Saline/Stress: $P = 1$), although there was an overall difference in L_a among the four groups (groups: $F_3 = 4.34$, $P = 0.017$; time: $F_{4.07} = 4.68$, $P = 0.002$; groups \times time: $F_{12.26} = 1.28$, $P = 0.246$; Fig. 2C).

Dark phase

Baseline T_c did not differ among the four groups including Saline/Stress ($n = 4$), Saline/Control ($n = 7$), Mepyramine/Stress ($n = 6$), and Mepyramine/Control ($n = 6$) groups. Mepyramine injection caused a marked decrease in postinjection T_c both in the control (baseline T_c : $38.07 \pm 0.06^\circ\text{C}$; postinjection T_c : $37.45 \pm 0.23^\circ\text{C}$; $t_5 = 3.31$, $P = 0.021$, paired t -test) and the stress group (baseline T_c : $38.21 \pm 0.05^\circ\text{C}$; postinjection T_c : $37.64 \pm 0.12^\circ\text{C}$; $t_5 = 4.61$, $P = 0.006$, paired t -testing). Two-way repeated measures ANOVA of the 60 min during the stress/control exposure followed by Bonferroni *post hoc* testing revealed that mepyramine significantly decreased T_c across time (groups: $F_3 = 17.19$, $P < 0.001$; time: $F_{2.3} = 13.14$, $P < 0.001$; groups \times time: $F_{6.89} = 4.82$, $P < 0.001$; Saline/Stress vs. Mepyramine/Stress: $P = 0.01$; Mepyramine/Control vs. Saline/Control: $P = 0.001$; Fig. 2B). However, mepyramine did not block the stress-induced increase in T_c as Bonferroni *post hoc* testing after two-way repeated measures ANOVA of the 60 min during the stress/control exposure, showing that there is a difference in T_c between the stressed and control rats injected with mepyramine (Mepyramine/Stress vs. Mepyramine/Control, $P = 0.008$). Furthermore, to compare only elevations of T_c during the stress/control exposure among the groups, ΔT_c was determined as the difference between the maximum and the nadir of T_c during the stress/control exposure. There was no difference in ΔT_c between the two stress groups (Saline/Stress: $0.98 \pm 0.14^\circ\text{C}$ vs. Mepyramine/Stress: $1.12 \pm 0.17^\circ\text{C}$, $P = 1$). The baseline L_a was not different among the four groups and IP injection of mepyramine did not affect the postinjection L_a in either group (Fig. 2D). Two-way repeated measures ANOVA of the 60 min during the stress/control exposure followed by Bonferroni *post hoc* testing revealed that there was no difference in L_a across time among the four groups and mepyramine did not affect the cage-exchange stress-induced change in L_a (groups: $F_3 = 1.88$, $P = 0.176$; time: $F_{4.27} = 5.76$, $P < 0.001$; groups \times time: $F_{12.82} = 1.78$, $P = 0.066$; Saline/Stress vs. Mepyramine/Stress: $P = 1$, Bonferroni *post hoc* test; Fig. 2D).

H2 receptor antagonist

Light phase

Baseline T_c did not differ among the four groups including Vehicle/Stress ($n = 4$), Vehicle/Control ($n = 4$), Cimetidine/Stress ($n = 5$), and Cimetidine/Control ($n = 5$) groups. IP injection of cimetidine did not affect the postinjection T_c in either the control group or the stress group. However, two-way repeated measures ANOVA of the 60 min during the stress/control exposure followed by Bonferroni *post hoc* testing revealed that cimetidine significantly attenuated the cage-exchange stress-induced increase in T_c (groups: $F_3 = 8.23$, $P = 0.002$; time: $F_{2.96} = 11.96$, $P < 0.001$; groups \times time: $F_{8.87} = 3.7$, $P = 0.002$; Vehicle/Stress vs. Cimetidine/Stress: $P = 0.028$; Fig. 3A). Baseline L_a and postinjection L_a were not different among the four groups (Fig. 3C). Two-way repeated measures ANOVA of the 60 min during the stress/control exposure followed by Bonferroni *post hoc* testing revealed that cimetidine did not affect the cage-exchange stress-induced increase in L_a (Cimetidine/Stress vs. Saline/Stress: $P = 1$), although there was an overall difference in L_a across time among the four groups (groups: $F_3 = 3.84$, $P = 0.034$; time: $F_{3.9} = 5.57$, $P = 0.001$; groups \times time: $F_{11.7} = 2.23$, $P = 0.023$; Fig. 3C).

Dark phase

Baseline T_c did not differ among the four groups including Vehicle/Stress ($n = 6$), Vehicle/Control ($n = 4$), Cimetidine/Stress ($n = 5$), and Cimetidine/Control ($n = 5$) groups. IP injection of cimetidine did not affect the postinjection T_c in either the control group or the stress group. Two-way repeated measures ANOVA of the 60 min during the stress/control exposure followed by Bonferroni *post hoc* testing revealed that cimetidine did not attenuate the cage-exchange stress-induced increase in T_c (groups: $F_3 = 17.01$, $P < 0.001$; time: $F_{2.86} = 4.05$, $P = 0.013$; groups \times time: $F_{8.58} = 4.23$, $P = 0.001$; Vehicle/Stress vs. Cimetidine/Stress: $P = 0.102$; Fig. 3B). Baseline L_a and postinjection L_a were not different among the four groups (Fig. 3D). Two-way repeated measures ANOVA of the 60 min during the stress/control exposure followed by Bonferroni *post hoc* testing revealed that cimetidine did not affect the cage-exchange stress-induced increase in L_a (Cimetidine/Stress vs. Vehicle/Stress: $P = 1$), although there was an overall difference in L_a among the four groups (groups: $F_3 = 11.31$, $P < 0.001$; time: $F_{5.35} = 5.58$, $P < 0.001$; groups \times time: $F_{16.05} = 2.21$, $P = 0.009$; Fig. 3D).




Figure 3. Effects of cimetidine on the cage-exchange stress-induced changes in T_c (A and B) and L_a (C and D) in light and dark phases. Rats ($n = 4-6$ per group) were administered with either an IP injection of 100 mg/kg cimetidine (triangles) or its vehicle (circles) at time -30 min (arrows), either exposed to cage-exchange stress (Stress: filled circles) or left undisturbed (Control: empty circles) at time zero for 60 min (black bar), then returned to their home cages in the light (A and C) and dark (B and D) phases. Each point represents mean \pm S.E.M. The differences in both T_c and L_a among the groups were compared using two-way repeated measures ANOVA followed by Bonferroni *post hoc* test. N in the parentheses = number of animals.

H3 receptor inverse agonist

Light phase

Baseline T_c did not differ among the four groups including Saline/Stress ($n = 8$), Saline/Control ($n = 8$), Ciproxifan/Stress ($n = 8$), and Ciproxifan/Control ($n = 8$) groups. IP injection of ciproxifan did not affect the postinjection T_c in either the control group or the stress group. Two-way repeated measures ANOVA of the 60 min during the stress/control exposure followed by Bonferroni *post hoc* testing revealed that ciproxifan did not attenuate the cage-exchange stress-induced increase in T_c , although there was an overall difference in T_c among the groups (groups: $F_3 = 18.75$, $P < 0.001$; time: $F_{1,3} = 9.05$, $P = 0.022$; groups \times time: $F_{4,1} = 5.9$, $P = 0.032$; Saline/Stress vs. Ciproxifan/Stress: $P = 0.327$; Fig. 4A). Baseline L_a and postinjection L_a were not different among the four groups (Fig. 4C). Two-way repeated measures ANOVA of the 60 min during the stress/control exposure followed by Bonferroni *post hoc* testing revealed that ciproxifan did not affect the cage-exchange stress-induced increase in L_a (Ciproxifan/Stress vs. Saline/Stress: $P = 0.505$), although there was an overall difference in L_a across time among the four groups (groups: $F_3 = 6.78$,

$P = 0.006$; time: $F_{2,8} = 3.45$, $P = 0.056$; groups \times time: $F_{8,4} = 1.15$, $P = 0.405$; Fig. 4C).

Dark phase

Baseline T_c did not differ among the four groups including Saline/Stress ($n = 8$), Saline/Control ($n = 8$), Ciproxifan/Stress ($n = 8$), and Ciproxifan/Control ($n = 8$) groups. IP injection of ciproxifan did not affect the postinjection T_c in either the control group or the stress group. Two-way repeated measures ANOVA of the 60 min during the stress/control exposure followed by Bonferroni *post hoc* testing revealed that ciproxifan did not attenuate the cage-exchange stress-induced increase in T_c , although there was an overall difference in T_c among the groups (groups: $F_3 = 4.61$, $P = 0.087$; time: $F_{2,1} = 3.77$, $P = 0.066$; groups \times time: $F_{6,4} = 2.73$, $P = 0.088$; Saline/Stress vs. Ciproxifan/Stress: $P = 1$; Fig. 4B). Baseline L_a was not different among the four groups (Fig. 4D). IP injection of ciproxifan did not affect the postinjection L_a in either the control group or the stress group. Two-way repeated measures ANOVA of the 60 min during the stress/control exposure followed by Bonferroni *post hoc* testing revealed that ciproxifan did




Figure 4. Effects of ciproxifan on the cage-exchange stress-induced changes in T_c (A and B) and L_a (C and D) in light and dark phases. Rats ($n = 8$ per group) were administered with either an IP injection of 10 mg/kg ciproxifan (triangles) or its vehicle (circles) at time -30 min (arrows), either exposed to cage-exchange stress (Stress: filled circles) or left undisturbed (Control: empty circles) at time zero for 60 min (black bar), then returned to their home cages in the light (A and C) and dark (B and D) phases. Each point represents mean \pm S.E.M. The differences in both T_c and L_a among the groups were compared using two-way repeated measures ANOVA followed by Bonferroni *post hoc* test. N in the parentheses = number of animals.

not attenuate the cage-exchange stress-induced increase in L_a , although there was an overall difference in L_a among the groups (groups: $F_3 = 5.11$, $P = 0.045$; time: $F_{3,2} = 8.78$, $P = 0.002$; groups \times time: $F_{9,8} = 1.41$, $P = 0.268$; Saline/Stress vs. Ciproxifan/Stress: $P = 1$; Fig. 4D).

Discussion

This study demonstrates that the histaminergic system is involved in the development of PSH, especially through H1 and H2 receptor systems. It also suggests that the roles of these receptors in PSH are different depending on circadian phase.

In the light phase, mepyramine, an H1 receptor inverse agonist, and cimetidine, an H2 receptor antagonist, attenuated cage-exchange stress-induced hyperthermia without affecting basal T_c . In contrast, ciproxifan, an H3 receptor inverse agonist, has no effect on the cage-exchange stress-induced hyperthermia or basal T_c . It was demonstrated that the DMH-rostral medullary raphe regions-sympathetic nerve axis plays an important role in the development of PSH (Lkhagvasuren et al. 2011; Kataoka et al. 2014). In contrast, the involvement of the preoptic area of the hypothalamus (POA), a thermoregulatory center, in the PSH has not been elucidated yet, whereas the POA

plays a crucial role in the development of fever when animals suffer from infectious diseases by disinhibiting the DMH-rostral medullary raphe regions-sympathetic nerve axis (Nakamura 2011; Saper et al. 2012; Morrison et al. 2014). So far, it is not known if histamine directly affects neuronal activities in the DMH or the rostral medullary raphe regions to induce PSH. In contrast, several studies have suggested that histamine acts on the neurons in the POA to induce hyperthermia. For example, in mice, intra-POA injection of histamine, 2-pyridylethylamine (an H1 receptor agonist), and R- α -methylhistamine (an H3 receptor agonist) increased T_c without affecting locomotor activity (Lundius et al. 2010). Another study demonstrated that, in mice, intra-POA injection of 2-pyridylethylamine and dimaprit (an H2 receptor agonist) increased T_c without affecting locomotor activity, whereas R- α -methylhistamine did not affect T_c (Tabarean et al. 2012). In rats, intra-POA injection of cimetidine attenuated hyperthermia induced by intracerebroventricular (ICV) injection of histamine (Colboc et al. 1982). These findings suggest that H1 and H2 receptors in the POA mediate the hyperthermic effects of histamine, despite the fact that the role of H3 receptors appears inconclusive. Considering that many kinds of stress activate histaminergic neurons in the TMN (Miklos and Kovacs 2003), it is possible that the histaminergic neurons projecting from

the TMN to the POA contribute to the development of PSH via H1 and H2 receptors.

Many kinds of psychological stress, including cage-exchange stress, increase arousal level in animals. Recently, motivated arousal, which was evoked by enticing hungry animals with food, was demonstrated to increase T_c by activating the infralimbic cortex (IL) and the TMN (Valdes et al. 2010; Riveros et al. 2014, 2015). Furthermore, IL activation-induced hyperthermia was attenuated by ICV injection of mepyramine (Riveros et al. 2014). These findings suggest that H1 receptors play an important role in increased arousal-associated hyperthermia as well as PSH.

In the dark phase, however, the effects of mepyramine and cimetidine on basal T_c or PSH were not the same as effects in the light phase. First, mepyramine decreased basal T_c that prevented the maximum increase in T_c to remain within the normothermic range, although it did not block the cage exchange-induced increase in T_c in the dark phase (Fig. 2B). However, it inhibited PSH without affecting basal T_c in the light phase. Second, cimetidine did not affect the cage exchange-induced hyperthermia in the dark phase, whereas it attenuated PSH in the light phase. So far, the precise mechanisms for these differences are not known. However, these phenomena, at least in the case of H1 receptor-mediated effects, may be associated with characteristics of the TMN neurons, whose firing rate is increased during the dark phase and decreased or absent during the light phase (Mochizuki et al. 1992; Takahashi et al. 2006). In accordance with this, histamine levels in the anterior hypothalamus and locomotor activity are higher in the dark phase than the light phase (Mochizuki et al. 1992; Takahashi et al. 2006). Mepyramine was demonstrated to decrease wakefulness and increase deep slow wave sleep (Lin et al. 1988), suggesting the involvement of H1 receptors in wakefulness. Furthermore, given the involvement of H1 receptors in arousal-associated hyperthermia into account, it is reasonable to think that mepyramine reduced T_c in the dark phase down to that of the basal level observed in the light phase (around 37.0°C).

We also investigated the effects of antihistaminergic drugs on stress-induced hyperkinesis. Baseline activity was higher in the dark phase versus the light phase. None of the drugs we administered affects L_a in either circadian phase, at least with the doses we tested. These findings are in agreement with the majority of previous studies demonstrating that antihistaminergic drugs do not affect locomotor activity in either phase (Sakai et al. 1991; Imaizumi et al. 1996; Perez-Garcia et al. 1999), despite several conflicting results (O'Neill and Gertner 1987; Riveros et al. 2014). Therefore, the inhibitory effects of mepyramine and cimetidine on PSH are not likely due to decreased locomotor activity.

There are several limitations of this study. First, we investigated the role of H receptors in PSH via IP injection of H1, H2, and H3 receptor antagonists/inverse agonists. In this study, we administered mepyramine, an H1 receptor inverse agonist, to assess the role of H1 receptors. It is because highly selective H1 antagonists are not available and its apparent constitutive activity of H1 receptors is low (Seifert et al. 2013), so the inverse agonist, mepyramine likely served as an H1 antagonist exerting a limited inverse-agonistic effect.

One of the reasons we injected drugs systemically was to explore the possibility of these drugs being a translational treatment of psychogenic fever in humans (Oka et al. 2001; Oka 2015). However, there remains a possibility that systemic injection of H receptor antagonists/inverse agonists affects the thermoregulatory responses according to their peripheral actions (such as vasodilation), especially through H1 and H2 receptors (Owen et al. 1980). In the current set of experiments, this is unlikely because, if this is the case, IP injection of mepyramine or cimetidine should decrease the postinjection T_c in the light phase. To negate the possibility of peripheral actions fully, these findings should be reconfirmed by ICV injection of these drugs. Secondly, although this study strongly suggests that the histaminergic system is involved in the development of PSH, its underlying mechanisms are not fully understood, especially as to how the histaminergic system affects the DMH-rostral medullary raphe regions-sympathetic axis.

In conclusion, this study demonstrated that the histaminergic system is involved in PSH, especially via H1 and H2 receptors. However, the role of these receptors in the development of PSH may be different depending on the circadian phase.

Clinical implication and significance

This study provides a substantial contribution to the understanding of the thermoregulatory mechanisms underlying autonomic and behavioral responses to psychological stress. Furthermore, the present findings suggest new therapeutic agents, antihistaminergic drugs, to alleviate stress-related disorders such as psychogenic fever (or functional hyperthermia), which is characterized by an antipyretic drug-resistant intense or long-lasting hyperthermia in stressful situations that is accompanied by an impaired quality of life (Timmerman et al. 1992; Oka and Oka 2007; Lkhagvasuren et al. 2013; Oka 2015).

Conflict of Interest

None declared.

References

- Bishop, D. 2003. Warm up I: potential mechanisms and the effects of passive warm up on exercise performance. *Sports Med.* 33:439–454.
- Briese, E., and M. G. de Quijada. 1970. Colonic temperature of rats during handling. *Acta Physiol. Lat. Am.* 20:97–102.
- Cannon, B., and J. Nedergaard. 2004. Brown adipose tissue: function and physiological significance. *Physiol. Rev.* 84:277–359.
- Clark, W. G., and Y. L. Clark. 1980. Changes in body temperature after administration of acetylcholine, histamine, morphine, prostaglandins and related agents. *Neurosci. Biobehav. Rev.* 4:175–240.
- Clark, W. G., and J. M. Lipton. 1985. Changes in body-temperature after administration of Acetylcholine, Histamine, Morphine, Prostaglandins and Related Agents. 2. *Neurosci. Biobehav. Rev.* 9:479–552.
- Colboc, O., P. Protais, and J. Costentin. 1982. Histamine-induced rise in core temperature of chloral-anaesthetized rats: mediation by H₂-receptors located in the preopticus area of hypothalamus. *Neuropharmacology* 21:45–50.
- Esbenshade, T. A., G. B. Fox, K. M. Krueger, J. L. Baranowski, T. R. Miller, C. H. Kang, et al. 2004. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H₃ receptor antagonist. *Biochem. Pharmacol.* 68:933–945.
- Fox, G. B., T. A. Esbenshade, J. B. Pan, R. J. Radek, K. M. Krueger, B. B. Yao, et al. 2005. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzotrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H₃ receptor antagonist. *J. Pharmacol. Exp. Ther.* 313:176–190.
- Groenink, L., J. Compaan, J. van der Gugten, T. Zethof, J. van der Heyden, and B. Olivier. 1995. Stress-induced hyperthermia in mice. Pharmacological and endocrinological aspects. *Ann. N. Y. Acad. Sci.* 771:252–256.
- Haas, H. L., O. A. Sergeeva, and O. Selbach. 2008. Histamine in the nervous system. *Physiol. Rev.* 88:1183–1241.
- Haruyama, W., T. Fuchigami, Y. Noguchi, A. Endo, K. Hashimoto, Y. Inamo, et al. 2008. The relationship between drug treatment and the clinical characteristics of febrile seizures. *World J. Pediatr.* 4:202–205.
- Hill, S. J., C. R. Ganellin, H. Timmerman, J. C. Schwartz, N. P. Shankley, J. M. Young, et al. 1997. International Union of Pharmacology. XIII. *Pharmacol. Rev.* 49:253–278.
- Hiramoto, T., T. Oka, K. Yoshihara, and C. Kubo. 2009. Pyrogenic cytokines did not mediate a stress interview-induced hyperthermic response in a patient with psychogenic fever: a case report. *Psychosom. Med.* 71:932–936.
- Hough, L. B., S. D. Glick, and K. Su. 1985. A role for histamine and histamine H₂-receptors in non-opiate footshock-induced analgesia. *Life Sci.* 36:859–866.
- Houtepen, L. C., D. P. Peterse, K. G. Westphal, B. Olivier, and C. H. Vinkers. 2011. The autonomic stress-induced hyperthermia response is not enhanced by several anxiogenic drugs. *Physiol. Behav.* 102:105–109.
- Imaizumi, M., S. Miyazaki, and K. Onodera. 1996. Effects of betahistine, a histamine H₁ agonist and H₃ antagonist, in a light/dark test in mice. *Methods Find. Exp. Clin. Pharmacol.* 18:19–24.
- Kamei, C., M. Ohuchi, Y. Sugimoto, and C. Okuma. 2000. Mechanism responsible for epileptogenic activity by first-generation H₁-antagonists in rats. *Brain Res.* 887:183–186.
- Kaneda, Y., S. Tsuji, and T. Oka. 2009. Age distribution and gender differences in psychogenic fever patients. *Biopsychosoc. Med.* 3:6.
- Kataoka, N., H. Hioki, T. Kaneko, and K. Nakamura. 2014. Psychological stress activates a dorsomedial hypothalamus-medullary raphe circuit driving brown adipose tissue thermogenesis and hyperthermia. *Cell Metab.* 20:346–358.
- Ligneau, X., J. Lin, G. Vanni-Mercier, M. Jouvet, J. L. Muir, C. R. Ganellin, et al. 1998. Neurochemical and behavioral effects of ciproxifan, a potent histamine H₃-receptor antagonist. *J. Pharmacol. Exp. Ther.* 287:658–666.
- Lin, J. S., K. Sakai, and M. Jouvet. 1988. Evidence for histaminergic arousal mechanisms in the hypothalamus of cat. *Neuropharmacology* 27:111–122.
- Lkhagvasuren, B., Y. Nakamura, T. Oka, N. Sudo, and K. Nakamura. 2011. Social defeat stress induces hyperthermia through activation of thermoregulatory sympathetic premotor neurons in the medullary raphe region. *Eur. J. Neurosci.* 34:1442–1452.
- Lkhagvasuren, B., T. Masuno, Y. Kanemitsu, N. Sudo, C. Kubo, and T. Oka. 2013. Increased prevalence of postural orthostatic tachycardia syndrome in psychogenic fever patients. *Psychother. Psychosom.* 82:269–270.
- Lkhagvasuren, B., T. Oka, Y. Nakamura, H. Hayashi, N. Sudo, and K. Nakamura. 2014. Distribution of Fos-immunoreactive cells in rat forebrain and midbrain following social defeat stress and diazepam treatment. *Neuroscience* 272:34–57.
- Long, N. C., A. J. Vander, and M. J. Kluger. 1990a. Stress-induced rise of body temperature in rats is the same in warm and cool environments. *Physiol. Behav.* 47:773–775.
- Long, N. C., A. J. Vander, S. L. Kunkel, and M. J. Kluger. 1990b. Antiserum against tumor necrosis factor increases stress hyperthermia in rats. *Am. J. Physiol.* 258:R591–R595.
- Lundius, E. G., M. Sanchez-Alavez, Y. Ghochani, J. Klaus, and I. V. Tabarean. 2010. Histamine influences body temperature by acting at H₁ and H₃ receptors on distinct populations of preoptic neurons. *J. Neurosci.* 30:4369–4381.
- Masuoka, T., S. Saito, and C. Kamei. 2008. Participation of hippocampal ionotropic glutamate receptors in histamine H₁ (1) antagonist-induced memory deficit in rats. *Psychopharmacology* 197:107–114.

- McGinty, D., M. N. Alam, R. Szymusiak, M. Nakao, and M. Yamamoto. 2001. Hypothalamic sleep-promoting mechanisms: coupling to thermoregulation. *Arch. Ital. Biol.* 139:63–75.
- McNeil, G. N., L. H. Leighton, and A. M. Elkins. 1984. Possible psychogenic fever of 103.5 degrees F in a patient with borderline personality disorder. *Am. J. Psychiatry* 141:896–897.
- Miklos, I. H., and K. J. Kovacs. 2003. Functional heterogeneity of the responses of histaminergic neuron subpopulations to various stress challenges. *Eur. J. Neurosci.* 18:3069–3079.
- Mochizuki, T., A. Yamatodani, K. Okakura, A. Horii, N. Inagaki, and H. Wada. 1992. Circadian rhythm of histamine release from the hypothalamus of freely moving rats. *Physiol. Behav.* 51:391–394.
- Morisset, S., A. Rouleau, X. Ligneau, F. Gbahou, J. Tardivel-Lacombe, H. Stark, et al. 2000. High constitutive activity of native H3 receptors regulates histamine neurons in brain. *Nature* 408:860–864.
- Morrison, S. F., C. J. Madden, and D. Tupone. 2014. Central neural regulation of brown adipose tissue thermogenesis and energy expenditure. *Cell Metab.* 19:741–756.
- Nakamori, T., A. Morimoto, K. Morimoto, N. Tan, and N. Murakami. 1993. Effects of alpha- and beta-adrenergic antagonists on rise in body temperature induced by psychological stress in rats. *Am. J. Physiol.* 264:R156–R161.
- Nakamura, K. 2011. Central circuitries for body temperature regulation and fever. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 301:R1207–R1228.
- Oishi, R., Y. Itoh, and K. Saeki. 1992. Inhibition of histamine turnover by 8-OH-DPAT, buspirone and 5-hydroxytryptophan in the mouse and rat brain. *Naunyn Schmiedebergs Arch. Pharmacol.* 345:495–499.
- Oka, T. 2015. Psychogenic fever: how psychological stress affects body temperature in the clinical population. *Temperature* 2:10.
- Oka, T., and K. Oka. 2007. Age and gender differences of psychogenic fever: a review of the Japanese literature. *Biopsychosoc. Med.* 1:11.
- Oka, T., K. Oka, and T. Hori. 2001. Mechanisms and mediators of psychological stress-induced rise in core temperature. *Psychosom. Med.* 63:476–486.
- Oka, T., K. Oka, T. Kobayashi, Y. Sugimoto, A. Ichikawa, F. Ushikubi, et al. 2003. Characteristics of thermoregulatory and febrile responses in mice deficient in prostaglandin EP1 and EP3 receptors. *J. Physiol.* 551:945–954.
- O'Neill, K. A., and S. B. Gertner. 1987. Effects of centrally administered H2 antagonists on motor activity. *Pharmacol. Biochem. Behav.* 26:683–686.
- Owen, D. A., E. Poy, D. F. Woodward, and D. Daniel. 1980. Evaluation of the role of Histamine H1- and H2-receptors in cutaneous inflammation in the guinea-pig produced by histamine and mast cell degranulation. *Br. J. Pharmacol.* 69:615–623.
- Panula, P., and S. Nuutinen. 2013. The histaminergic network in the brain: basic organization and role in disease. *Nat. Rev. Neurosci.* 14:472–487.
- Perez-Garcia, C., L. Morales, M. V. Cano, I. Sancho, and L. F. Alguacil. 1999. Effects of histamine H3 receptor ligands in experimental models of anxiety and depression. *Psychopharmacology* 142:215–220.
- Riveros, M. E., G. Perdomo, and F. Torrealba. 2014. Infralimbic cortex controls core body temperature in a histamine dependent manner. *Physiol. Behav.* 128:1–8.
- Riveros, M. E., M. I. Forray, and F. Torrealba. 2015. Infralimbic cortex activation and motivated arousal induce histamine release. *Behav. Pharmacol.* 26:338–344.
- Sagar, S. M., F. R. Sharp, and T. Curran. 1988. Expression of c-fos protein in brain: metabolic mapping at the cellular level. *Science* 240:1328–1331.
- Sakai, N., K. Onodera, K. Maeyama, K. Yanai, and T. Watanabe. 1991. Effects of thioperamide, a histamine H3 receptor antagonist, on locomotor activity and brain histamine content in mast cell-deficient W/Wv mice. *Life Sci.* 48:2397–2404.
- Saper, C. B., A. A. Romanovsky, and T. E. Scammell. 2012. Neural circuitry engaged by prostaglandins during the sickness syndrome. *Nat. Neurosci.* 15:1088–1095.
- Schneider, E. H., and R. Seifert. 2016. The histamine H4-receptor and the central and peripheral nervous system: a critical analysis of the literature. *Neuropharmacology* 106:116–128.
- Seifert, R., A. Strasser, E. H. Schneider, D. Neumann, S. Dove, and A. Buschauer. 2013. Molecular and cellular analysis of human histamine receptor subtypes. *Trends Pharmacol. Sci.* 34:33–58.
- Snow, A. E., and A. Horita. 1982. Interaction of apomorphine and stressors in the production of hyperthermia in the rabbit. *J. Pharmacol. Exp. Ther.* 220:335–339.
- Tabarean, I. V., M. Sanchez-Alavez, and J. Sethi. 2012. Mechanism of H(2) histamine receptor dependent modulation of body temperature and neuronal activity in the medial preoptic nucleus. *Neuropharmacology* 63:171–180.
- Takahashi, K., J. S. Lin, and K. Sakai. 2006. Neuronal activity of histaminergic tuberomammillary neurons during wake-sleep states in the mouse. *J. Neurosci.* 26:10292–10298.
- Timmerman, R. J., J. Thompson, H. M. Noordzij, and J. W. van der Meer. 1992. Psychogenic periodic fever. *Neth. J. Med.* 41:158–160.
- Toyota, H., C. Dugovic, M. Koehl, A. D. Laposky, C. Weber, K. Ngo, et al. 2002. Behavioral characterization of mice lacking histamine H(3) receptors. *Mol. Pharmacol.* 62:389–397.
- Valdes, J. L., C. Sanchez, M. E. Riveros, P. Blandina, M. Contreras, P. Farias, et al. 2010. The histaminergic tuberomammillary nucleus is critical for motivated arousal. *Eur. J. Neurosci.* 31:2073–2085.

- Vinkers, C. H., L. Groenink, M. J. van Bogaert, K. G. Westphal, C. J. Kalkman, R. van Oorschot, et al. 2009. Stress-induced hyperthermia and infection-induced fever: two of a kind? *Physiol. Behav.* 98:37–43.
- Whittico, M. T., Y. A. Gang, and K. M. Giacomini. 1990. Cimetidine transport in isolated brush border membrane vesicles from bovine choroid plexus. *J. Pharmacol. Exp. Ther.* 255:615–623.
- Wright, K. P. JR., J. T. Hull, and C. A. Czeisler. 2002. Relationship between alertness, performance, and body temperature in humans. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 283:R1370–R1377.
- Yamazaki, M., H. Fukuoka, O. Nagata, H. Kato, Y. Ito, T. Terasaki, et al. 1994. Transport mechanism of an H1-antagonist at the blood-brain barrier: transport mechanism of mepyramine using the carotid injection technique. *Biol. Pharm. Bull.* 17:676–679.
- Yanai, K., L. Z. Son, M. Endou, E. Sakurai, O. Nakagawasai, T. Tadano, et al. 1998. Behavioural characterization and amounts of brain monoamines and their metabolites in mice lacking histamine H1 receptors. *Neuroscience* 87:479–487.
- Yokoi, Y. 1966. Effect of ambient temperature upon emotional hyperthermia and hypothermia in rabbits. *J. Appl. Physiol.* 21:1795–1798.
- Zethof, T. J., J. A. van der Heyden, J. T. Tolboom, and B. Olivier. 1995. Stress-induced hyperthermia as a putative anxiety model. *Eur. J. Pharmacol.* 294:125–135.